JP2022530264A5 - - Google Patents
Info
- Publication number
- JP2022530264A5 JP2022530264A5 JP2021564486A JP2021564486A JP2022530264A5 JP 2022530264 A5 JP2022530264 A5 JP 2022530264A5 JP 2021564486 A JP2021564486 A JP 2021564486A JP 2021564486 A JP2021564486 A JP 2021564486A JP 2022530264 A5 JP2022530264 A5 JP 2022530264A5
- Authority
- JP
- Japan
- Prior art keywords
- virus particle
- polynucleotide
- aav virus
- aav
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962840360P | 2019-04-29 | 2019-04-29 | |
| US62/840,360 | 2019-04-29 | ||
| PCT/US2020/030427 WO2020223322A1 (en) | 2019-04-29 | 2020-04-29 | Intrathecal and intravenous combination gene therapy for the treatment of infantile batten disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022530264A JP2022530264A (ja) | 2022-06-28 |
| JP2022530264A5 true JP2022530264A5 (OSRAM) | 2023-05-12 |
| JP7788594B2 JP7788594B2 (ja) | 2025-12-19 |
Family
ID=73029200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021564486A Active JP7788594B2 (ja) | 2019-04-29 | 2020-04-29 | 乳児バッテン病の治療のための髄腔内および静脈内組合せ遺伝子療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220193268A1 (OSRAM) |
| EP (1) | EP3963081A4 (OSRAM) |
| JP (1) | JP7788594B2 (OSRAM) |
| KR (1) | KR20220046513A (OSRAM) |
| CN (1) | CN114269935A (OSRAM) |
| AU (1) | AU2020264438A1 (OSRAM) |
| BR (1) | BR112021021632A8 (OSRAM) |
| CA (1) | CA3138274A1 (OSRAM) |
| IL (1) | IL287608A (OSRAM) |
| MX (1) | MX2021013275A (OSRAM) |
| SG (1) | SG11202111908XA (OSRAM) |
| WO (1) | WO2020223322A1 (OSRAM) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025524569A (ja) * | 2022-07-06 | 2025-07-30 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | Ｃｌｎ１ポリヌクレオチドのアデノ随伴ウイルス送達 |
| WO2024015794A2 (en) * | 2022-07-12 | 2024-01-18 | The Research Institute At Nationwide Children's Hospital | Adeno-associated virus gene therapy products and methods |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130195800A1 (en) * | 2010-03-23 | 2013-08-01 | Intrexon Corporation | Vectors Conditionally Expressing Therapeutic Proteins, Host Cells Comprising the Vectors, and Uses Thereof |
| US10876134B2 (en) * | 2014-12-16 | 2020-12-29 | Board Of Regents Of The University Of Nebraska | Gene therapy for juvenile batten disease |
| KR102629418B1 (ko) * | 2016-06-13 | 2024-01-25 | 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 | 최적화된 cln1 유전자 및 발현 카세트 및 그의 용도 |
| US20200370069A1 (en) * | 2017-07-08 | 2020-11-26 | Genethon | Treatment of spinal muscular atrophy |
| WO2019046815A1 (en) * | 2017-08-31 | 2019-03-07 | Poseida Therapeutics, Inc. | TRANSPOSON SYSTEM AND METHODS OF USE |
-
2020
- 2020-04-29 CA CA3138274A patent/CA3138274A1/en not_active Abandoned
- 2020-04-29 SG SG11202111908XA patent/SG11202111908XA/en unknown
- 2020-04-29 WO PCT/US2020/030427 patent/WO2020223322A1/en not_active Ceased
- 2020-04-29 KR KR1020217038864A patent/KR20220046513A/ko not_active Withdrawn
- 2020-04-29 MX MX2021013275A patent/MX2021013275A/es unknown
- 2020-04-29 AU AU2020264438A patent/AU2020264438A1/en active Pending
- 2020-04-29 JP JP2021564486A patent/JP7788594B2/ja active Active
- 2020-04-29 EP EP20798198.6A patent/EP3963081A4/en active Pending
- 2020-04-29 CN CN202080047719.4A patent/CN114269935A/zh active Pending
- 2020-04-29 US US17/607,315 patent/US20220193268A1/en active Pending
- 2020-04-29 BR BR112021021632A patent/BR112021021632A8/pt not_active Application Discontinuation
-
2021
- 2021-10-27 IL IL287608A patent/IL287608A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220331409A1 (en) | Factor ix gene therapy | |
| JP2022520232A5 (OSRAM) | ||
| JP2025179046A5 (OSRAM) | ||
| J. McCown | Adeno-associated virus (AAV) vectors in the CNS | |
| JP2022516283A5 (OSRAM) | ||
| US20250305001A1 (en) | Genetic Construct | |
| JP2021500922A5 (OSRAM) | ||
| JP2021533805A5 (OSRAM) | ||
| JP2023514242A5 (OSRAM) | ||
| RU2018145010A (ru) | Оптимизированные гены и экспрессионные кассеты cln1, и их применение | |
| JP2025512574A5 (OSRAM) | ||
| JP2022533448A5 (OSRAM) | ||
| JP2023503850A5 (OSRAM) | ||
| JP2022539156A (ja) | ヒアルロン酸を用いた眼組織へのａａｖ媒介形質導入の増強 | |
| JP2024546103A5 (OSRAM) | ||
| JP2024545507A5 (OSRAM) | ||
| EP3773748A1 (en) | Bicistronic aav vectors encoding hexosaminidase alpha and beta-subunits and uses thereof | |
| IL298772A (en) | Coding-optimized nucleic acid encoding the SMN1 protein and its use | |
| EP4509606A1 (en) | Nucleic acid construct for treating hereditary coagulation factor deficiency and use thereof | |
| CA3178591A1 (en) | Immunosuppressive agents and viral delivery re-dosing methods for gene therapy | |
| JP2022530359A5 (OSRAM) | ||
| JP2023526923A5 (OSRAM) | ||
| JP2023536067A5 (OSRAM) | ||
| JP2025504478A5 (OSRAM) | ||
| JP2025503868A5 (OSRAM) |